









Markets
/
Stocks
/
nasdaq-catx
/

Perspective Therapeutics Inc

CATX

3.290USD

+0.250+8.22%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

244.33MMarket Cap

LossP/E TTM



Perspective Therapeutics Inc

3.290

+0.250+8.22%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

112 / 507

Overall Ranking

231 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

13.462

Target Price

+311.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. It is also developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.45M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 990.20.

Fairly Valued

The company’s latest PE is -2.24, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 59.55M shares, decreasing 16.57% quarter-over-quarter.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 6.19, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 290.00K, representing a year-over-year decrease of 44.87%, while its net profit experienced a year-over-year decrease of 83.57%.

Score

Industry at a Glance

Previous score

6.21

Change

-0.02



Financials

6.27

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.60

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.28

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.15

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.24, which is -6.65% below the recent high of -2.09 and -21.46% above the recent low of -2.72.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 112/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Perspective Therapeutics Inc is 14.00, with a high of 20.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 13 analysts

Buy

Current Rating

13.462

Target Price

+342.81%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Perspective Therapeutics Inc

CATX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.42, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 3.59 and the support level at 2.76, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.47

Change

-0.05

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.021

Sell

RSI(14)

45.272

Neutral

STOCH(KDJ)(9,3,3)

26.512

Neutral

ATR(14)

0.252

High Vlolatility

CCI(14)

-109.761

Sell

Williams %R

67.470

Sell

TRIX(12,20)

-0.452

Sell

StochRSI(14)

53.836

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

3.334

Sell

MA10

3.354

Sell

MA20

3.421

Sell

MA50

3.718

Sell

MA100

3.346

Sell

MA200

3.133

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Lantheus Holdings, Inc.

11.68M

Fidelity Management & Research Company LLC

7.86M

+0.93%

Fidelity Institutional Asset Management

2.20M

-2.19%

BlackRock Institutional Trust Company, N.A.

3.70M

-0.91%

The Vanguard Group, Inc.

Star Investors

3.07M

-2.08%

Nuveen LLC

1.23M

+72.75%

Avidity Partners Management LP

2.20M

-18.46%

Nicholson Wealth Management Group, LLC

1.61M

Morgan Stanley & Co. LLC

1.47M

+29.87%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 2.98, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.16. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.